
Yu Kataoka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/625743/publications.pdf Version: 2024-02-01



ΥΠ ΚΑΤΛΟΚΑ

#	Article	IF	CITATIONS
1	Impact of Statins on Serial Coronary Calcification During Atheroma ProgressionÂand Regression. Journal of the American College of Cardiology, 2015, 65, 1273-1282.	1.2	467
2	Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis. Journal of the American College of Cardiology, 2012, 59, 1592-1597.	1.2	164
3	Non-HDL Cholesterol and Triglycerides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2220-2228.	1.1	119
4	Coronary Artery Ectasia Predicts Future Cardiac Events in Patients With Acute Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 2350-2355.	1.1	93
5	Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. American Journal of Cardiovascular Drugs, 2016, 16, 55-65.	1.0	82
6	Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension. JAMA - Journal of the American Medical Association, 2013, 310, 1135.	3.8	67
7	Spotty calcification and plaque vulnerability in vivo: frequency-domain optical coherence tomography analysis. Cardiovascular Diagnosis and Therapy, 2014, 4, 460-9.	0.7	63
8	Atheroma Progression in Hyporesponders to Statin Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 990-995.	1.1	58
9	Sex-Related Differences of Coronary Atherosclerosis Regression Following Maximally Intensive Statin Therapy. JACC: Cardiovascular Imaging, 2014, 7, 1013-1022.	2.3	54
10	High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN. Diabetes Care, 2014, 37, 3114-3120.	4.3	50
11	Sex Differences in Nonculprit Coronary Plaque Microstructures on Frequency-Domain Optical Coherence Tomography in Acute Coronary Syndromes and Stable Coronary Artery Disease. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	49
12	Near-Infrared Spectroscopy Enhances Intravascular Ultrasound Assessment of Vulnerable Coronary Plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2423-2431.	1.1	48
13	Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. Atherosclerosis, 2015, 242, 490-495.	0.4	43
14	Impact of Baseline Lipoprotein and C-Reactive Protein Levels on Coronary Atheroma Regression Following High-Intensity Statin Therapy. American Journal of Cardiology, 2014, 114, 1465-1472.	0.7	42
15	Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden. Cardiovascular Diagnosis and Therapy, 2017, 7, 252-263.	0.7	42
16	Antiatherosclerotic Effects of Long-Term Maximally Intensive Statin Therapy After Acute Coronary Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2465-2472.	1.1	41
17	Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: Insights from intravascular ultrasound. Atherosclerosis, 2014, 232, 377-383.	0.4	40
18	Frequency-Domain Optical Coherence Tomographic Analysis of Plaque Microstructures at Nonculprit Narrowings in Patients Receiving Potent Statin Therapy. American Journal of Cardiology, 2014, 114, 549-554.	0.7	37

Υυ ΚΑΤΑΟΚΑ

#	Article	IF	CITATIONS
19	Cardiac outcomes in patients with acute coronary syndrome attributable to calcified nodule. Atherosclerosis, 2021, 318, 70-75.	0.4	37
20	Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. European Journal of Preventive Cardiology, 2013, 20, 209-217.	0.8	26
21	Progression of coronary atherosclerosis in stable patients with ultrasonic features of high-risk plaques. European Heart Journal Cardiovascular Imaging, 2014, 15, 1035-1041.	0.5	25
22	The Extent of Aortic Atherosclerosis Predicts the Occurrence, Severity, and Recovery of Acute Kidney Injury After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2018, 11, e006367.	1.4	19
23	Progression of ultrasound plaque attenuation and low echogenicity associates with major adverse cardiovascular events. European Heart Journal, 2020, 41, 2965-2973.	1.0	19
24	Predicting Parameters for Successful Weaning from Venoâ€Arterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock. ESC Heart Failure, 2021, 8, 471-480.	1.4	16
25	Inflammation, plaque progression and vulnerability: evidence from intravascular ultrasound imaging. Cardiovascular Diagnosis and Therapy, 2015, 5, 280-9.	0.7	16
26	Aortic atheroma burden predicts acute cerebrovascular events after transcatheter aortic valve implantation: insights from volumetric multislice computed tomography analysis. EuroIntervention, 2016, 12, 783-789.	1.4	14
27	The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events. European Journal of Preventive Cardiology, 2016, 23, 474-485.	0.8	12
28	Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 413-421.e3.	0.6	12
29	In vivo imaging of vulnerable plaque with intravascular modalities: its advantages and limitations. Cardiovascular Diagnosis and Therapy, 2020, 10, 1461-1479.	0.7	12
30	Elevated Lipoprotein(a) as a potential residual risk factor associated with lipid-rich coronary atheroma in patients with type 2 diabetes and coronary artery disease on statin treatment: Insights from the REASSURE-NIRS registry. Atherosclerosis, 2022, 349, 183-189.	0.4	12
31	In vivovisualization of lipid coronary atheroma with intravascular near-infrared spectroscopy. Expert Review of Cardiovascular Therapy, 2017, 15, 775-785.	0.6	11
32	Achieving better modulation of coronary atherosclerosis: its understanding, visualization and treatment. Cardiovascular Diagnosis and Therapy, 2016, 6, 280-281.	0.7	9
33	Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy. Journal of the American Heart Association, 2021, 10, e019525.	1.6	8
34	Current imaging modalities for atherosclerosis. Expert Review of Cardiovascular Therapy, 2012, 10, 457-471.	0.6	7
35	Plaque vulnerability at non-culprit lesions in obese patients with coronary artery disease: Frequency-domain optical coherence tomography analysis. European Journal of Preventive Cardiology, 2015, 22, 1331-1339.	0.8	7
36	Plaque burden, microstructures and compositions underachieving very low LDL-C levels. Current Opinion in Endocrinology, Diabetes and Obesity, 2017, 24, 122-132.	1.2	7

Υυ ΚΑΤΑΟΚΑ

#	Article	IF	CITATIONS
37	The feasibility and limitation of coronary computed tomographic angiography imaging to identify coronary lipid-rich atheroma in vivo: Findings from near-infrared spectroscopy analysis. Atherosclerosis, 2021, 322, 1-7.	0.4	7
38	Substantially Elevated Atherosclerotic Risks in Japanese Severe Familial Hypercholesterolemia Defined by the International Atherosclerosis Society. JACC Asia, 2021, 1, 245-255.	0.5	7
39	Progression of coronary atherosclerosis in African-American patients. Cardiovascular Diagnosis and Therapy, 2013, 3, 161-9.	0.7	7
40	Imaging of atherosclerotic plaques in obesity: excessive fat accumulation, plaque progression and vulnerability. Expert Review of Cardiovascular Therapy, 2014, 12, 1471-1489.	0.6	6
41	Cholesterol crystal-induced coronary inflammation: Insights from optical coherence tomography and pericoronary adipose tissue computed tomography attenuation. Journal of Cardiovascular Computed Tomography, 2020, 14, 277-278.	0.7	6
42	Refractory In-Stent Restenosis Attributable to Eruptive Calcified Nodule. JACC: Case Reports, 2020, 2, 1872-1878.	0.3	5
43	How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?. Journal of Atherosclerosis and Thrombosis, 2022, 29, 795-807.	0.9	5
44	Suspected Hypersensitivity Reaction Following Drug-Eluting Stent Implantation. JACC: Cardiovascular Interventions, 2012, 5, e21-e23.	1.1	4
45	Comparing Coronary Atheroma Progression Rates and Coronary Events in the United States, Canada, Latin America, and Europe. American Journal of Cardiology, 2016, 118, 1616-1623.	0.7	4
46	Chronic kidney disease and coronary atherosclerosis: evidences from intravascular imaging. Expert Review of Cardiovascular Therapy, 2019, 17, 707-716.	0.6	4
47	Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis, 2015, 243, 553-559.	0.4	3
48	Non-invasive volumetric assessment of aortic atheroma: a core laboratory validation using computed tomography angiography. International Journal of Cardiovascular Imaging, 2016, 32, 121-129.	0.7	3
49	In vivo visualization of braid-like appearance in Kawasaki disease: insights from multi-modality imaging. International Journal of Cardiovascular Imaging, 2017, 33, 1891-1893.	0.7	2
50	Plaque erosion or coronary artery embolism? Findings from clinical presentation, optical coherence tomographic and histopathological analysis in a case with acute coronary syndrome. International Journal of Cardiovascular Imaging, 2019, 35, 1791-1792.	0.7	2
51	Coronary artery ectasia: Importance of its risk stratification and management. International Journal of Cardiology, 2021, 322, 43-44.	0.8	2
52	Suboptimal lipoprotein (a) control and residual plaque instability despite proprotein convertase subtilisin/kexin type 9 inhibitor use in heterozygous familial hypercholesterolaemia: insights from serial near-infrared spectroscopy imaging. European Heart Journal, 2021, 42, 2218-2219.	1.0	2
53	The Residual Lipid-Rich Coronary Atheroma Behind the Implanted Newer-Generation Drug-Eluting Stent and Future Stent-Related Event Risks. Canadian Journal of Cardiology, 2022, 38, 1504-1515.	0.8	2
54	The impact of lumen size and microvascular resistance on Fourier-domain optical coherence tomography (FD-OCT) coronary measurements. International Journal of Cardiology, 2014, 174, 210-211.	0.8	1

Υυ ΚΑΤΑΟΚΑ

#	Article	IF	CITATIONS
55	Embolization of Neoatherosclerosis After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e006175.	1.4	1
56	Serial changes in vessel walls of renal arteries after catheter-based renal artery denervation: insights from volumetric computed tomography analysis. International Journal of Nephrology and Renovascular Disease, 2018, Volume 11, 259-266.	0.8	1
57	Erupted coronary atheroma: insights from multi-modality imaging. International Journal of Cardiovascular Imaging, 2018, 34, 1669-1671.	0.7	1
58	Reduction of lipoprotein(a) with proprotein convertase subtilisin/kexin type 9 inhibitor as a potential contributor to modulating coronary inflammatory activity: insights from serial pericoronary adipose tissue analysis. European Heart Journal, 2022, 43, 1597-1597.	1.0	1
59	Continuous improvement of both hepatic and cardiac dysfunction by sequential plasma exchange in a patient with thyrotoxicosis and cardiogenic shock: a case report indicating the potential role of cardiohepatic interactions during thyroid storm. European Heart Journal - Case Reports, 2022, 6, .	0.3	1
60	Lipidomics: Opportunities to Identify New Causal Mechanisms and Therapeutics for Atherosclerosis. Current Cardiovascular Risk Reports, 2013, 7, 60-65.	0.8	0
61	Better Risk Stratification for Patients With Complex Coronary Artery Disease. Circulation Journal, 2014, 78, 1832-1833.	0.7	0
62	Trans fatty acids and plaque vulnerability: Research continues. Atherosclerosis, 2017, 265, 244-245.	0.4	0
63	Marking Technique for Identification of Optimal Stent Landing Site With OpticalÂCoherence Tomographic Imaging. JACC: Cardiovascular Interventions, 2018, 11, e79-e80.	1.1	0
64	Temporal Changes in Near-Infrared Spectroscopy Signals in Recurrent In-Stent Restenosis Attributable to Calcified Nodule. Canadian Journal of Cardiology, 2021, 37, 1880-1881.	0.8	0
65	Heart Team Intervention for Calcified Left Main Coronary Disease and Jeopardized Left Internal Mammary Artery Graft. Case Reports in Cardiology, 2022, 2022, 1-5.	0.1	0